Sequential

DermTech Reports Second Quarter 2021 Financial Results

Retrieved on: 
Wednesday, August 4, 2021

Billable sample volume of approximately 11,750 for the second quarter of 2021, a 267% increase compared to approximately 3,200 recorded for the second quarter of 2020 and a 25% sequential increase over the first quarter of 2021.

Key Points: 
  • Billable sample volume of approximately 11,750 for the second quarter of 2021, a 267% increase compared to approximately 3,200 recorded for the second quarter of 2020 and a 25% sequential increase over the first quarter of 2021.
  • Assay revenue of $2.9 million for the second quarter of 2021, a 349% increase compared to the second quarter of 2020 and a 33% sequential increase over the first quarter of 2021.
  • Total revenue of $3.1 million for the second quarter of 2021, a 269% increase compared to the second quarter of 2020 and a 24% sequential increase over the first quarter of 2021.
  • DermTech will host a conference call and webcast to discuss the second quarter financial results on Wednesday, August 4, 2021 at 1:30 p.m. Pacific time / 4:30 p.m. Eastern time.

Intersect ENT Announces Preliminary Revenue for Second Quarter of 2021 and Closing of $60 Million Term Loan

Retrieved on: 
Thursday, July 22, 2021

Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (ENT) medical technology leader dedicated to transforming patient care, today announced preliminary second quarter 2021 revenue and provided a business update.

Key Points: 
  • Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (ENT) medical technology leader dedicated to transforming patient care, today announced preliminary second quarter 2021 revenue and provided a business update.
  • Cash, cash equivalents, restricted cash, and short-term investments of approximately $76.2 million as of June 30, 2021.
  • "As the broader economy opens up, our preliminary second quarter results reflect strong sequential performance across our business, growth relative to the second quarter of 2019, and record SINUVA revenues, said Thomas A.
  • Intersect ENT announced today that it entered into a $60 million secured term loan agreement with a fund managed by Deerfield Management Company L.P. (Deerfield).

1847 Goedeker Continues Strong 2021 Performance with Monthly Record June Revenues up 47.8% to $55.7 Million

Retrieved on: 
Monday, July 12, 2021

June 2021 monthly orders increased 19.2% from the prior year period to $73.2 million while June 2021 monthly revenues totaled $55.7 million, representing a 47.8% increase over the June 2020 results.

Key Points: 
  • June 2021 monthly orders increased 19.2% from the prior year period to $73.2 million while June 2021 monthly revenues totaled $55.7 million, representing a 47.8% increase over the June 2020 results.
  • "We are incredibly pleased with the continued strong momentum during the first half of this year, as June marks a record performance for the organization," stated Doug Moore, CEO of Goedekers.
  • "Throughout the past month, we have experienced a significantly improved fill rate of 76.1%, up from 61.4% in June of 2020, along with record shipments.
  • We are encouraged by the sequential progress we made in revenue achievement versus orders as the fill rate of 76.1% is at its highest level for 2021.

ClearOne Reports First Quarter 2021 Financial Results

Retrieved on: 
Thursday, May 13, 2021

b'SALT LAKE CITY, May 13, 2021 (GLOBE NEWSWIRE) -- ClearOne (NASDAQ: CLRO), a global provider of audio and visual communication solutions, reported financial results for the three months ended March 31, 2021.\n"The first quarter of 2021 continued our trend of year-over-year growth and the successful execution of our strategic imperatives.

Key Points: 
  • b'SALT LAKE CITY, May 13, 2021 (GLOBE NEWSWIRE) -- ClearOne (NASDAQ: CLRO), a global provider of audio and visual communication solutions, reported financial results for the three months ended March 31, 2021.\n"The first quarter of 2021 continued our trend of year-over-year growth and the successful execution of our strategic imperatives.
  • The excitement, acceptance, and adoption of this new product has exceeded our initial market expectations.
  • The BMA 360 is based on a dramatically new approach to beamforming that provides a new beam topology to easily achieve distortion-free, full 360-degree coverage of any room shape and any seating arrangement using ClearOne Audio Intelligence\xe2\x84\xa2.
  • The sequential and year-over-year decline in GAAP net loss was primarily due to increase in gross profit attributable to increase in revenue.\nThree months ended March 31,\n'

Redline Communications Reports 2021 First Quarter Results Achieved Record Gross Margins

Retrieved on: 
Wednesday, May 12, 2021

b'Due to consistent sequential strength in building recurring revenue streams over the previous eight quarters, the company achieved record gross margins of 69% in the quarter, resulting in an increase of 6 percentage points compared to Q1 2020.\nOperating expenses for Q1 2021 were $3.9 million, down 5% over Q1 2020.

Key Points: 
  • b'Due to consistent sequential strength in building recurring revenue streams over the previous eight quarters, the company achieved record gross margins of 69% in the quarter, resulting in an increase of 6 percentage points compared to Q1 2020.\nOperating expenses for Q1 2021 were $3.9 million, down 5% over Q1 2020.
  • This investment brings up to CDN $14 million into the Company, earmarked for the development of an innovative industrial 5G network solution.
  • Under the terms of the agreement, the fund will reimburse 41.52% of eligible R&D costs (labor, equipment and materials) incurred by Redline.
  • "\nConference Call and Webcast May 13, 2021 at 10:00 a.m. ET\nA conference call and webcast to discuss the results has been scheduled for Thursday, May 13, 2021 at 10:00 a.m. Eastern Time.

GBT Reports First Quarter 2021 Financial Results

Retrieved on: 
Wednesday, May 5, 2021

Despite the headwinds we expected from the COVID-19 pandemic during the quarter, we continue to deliver new prescriptions, and the net number of patients on Oxbryta has increased each quarter since launch.

Key Points: 
  • Despite the headwinds we expected from the COVID-19 pandemic during the quarter, we continue to deliver new prescriptions, and the net number of patients on Oxbryta has increased each quarter since launch.
  • Basic and diluted net loss per share for the three months ended\xc2\xa0March 31, 2021, was\xc2\xa0$1.21\xc2\xa0compared with\xc2\xa0$1.20\xc2\xa0for the same period in 2020.
  • GBT anticipates a sequential increase in operating expenses in the second quarter of 2021 as the company continues to ramp up these efforts.\nCash, cash equivalents, and marketable securities totaled\xc2\xa0$482.0 million\xc2\xa0at\xc2\xa0March 31, 2021, compared with\xc2\xa0$560.9 million\xc2\xa0at\xc2\xa0December 31, 2020.\nGBT will host a conference call today, Wednesday, May 5, 2021, at 4:30 p.m.
  • ET to provide a general business update and discuss the financial results for the first quarter 2021.

MediPharm Labs Reports Fourth Quarter and Full Year 2020 Results

Retrieved on: 
Wednesday, March 31, 2021

MediPharm Labs took significant actions in Q4 2020 that will allow for more efficient operations as the Company made strong progress building its presence in the pharmaceutical, medical and wellness markets and executing on international customer agreements including STADA.

Key Points: 
  • MediPharm Labs took significant actions in Q4 2020 that will allow for more efficient operations as the Company made strong progress building its presence in the pharmaceutical, medical and wellness markets and executing on international customer agreements including STADA.
  • Greg Hunter, Chief Financial Officer, MediPharm Labs, commented, We are encouraged by the sequential increase in fourth quarter revenue reflecting the growth of our manufacturing and white label business.
  • In addition to the completion of cost reduction initiatives in the quarter, we are confident that our sales, product innovations and fiscal management will return us to profitability.
  • MediPharm Labs executive management team will host a conference call and audio webcast to discuss the results and outlook for its fourth quarter and year ended December 31, 2020 on Wednesday, March 31, 2021, at 8:30 a.m. eastern time
    Audio Conference Call Dial In Details:

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Sequential Brands Group, Inc. (SQBG)

Retrieved on: 
Tuesday, March 16, 2021

NEW YORK, March 16, 2021 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Sequential Brands Group, Inc. (Sequential Brands) (NASDAQ: SQBG) in the United States District Court for the Southern District of New York on behalf of those who purchased or acquired the securities of Sequential Brands between November 3, 2016 and December 11, 2020, inclusive (the Class Period).

Key Points: 
  • NEW YORK, March 16, 2021 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Sequential Brands Group, Inc. (Sequential Brands) (NASDAQ: SQBG) in the United States District Court for the Southern District of New York on behalf of those who purchased or acquired the securities of Sequential Brands between November 3, 2016 and December 11, 2020, inclusive (the Class Period).
  • Investors who purchased or otherwise acquired shares of Sequential Brands during the Class Period should contact the Firm prior to the May 17, 2021 lead plaintiff motion deadline.
  • If you wish to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq.
  • of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected] .

SEQUENTIAL BRANDS INVESTOR ALERT: Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Sequential Brands To Contact Him Directly To Discuss Their Options

Retrieved on: 
Saturday, January 23, 2021

NEW YORK, Jan. 23, 2021 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading minority and certified woman-owned national securities law firm, is investigating potential claims against Sequential Brands Group, Inc. (Sequential Brands or the Company) (NASDAQ:SQBG).

Key Points: 
  • NEW YORK, Jan. 23, 2021 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading minority and certified woman-owned national securities law firm, is investigating potential claims against Sequential Brands Group, Inc. (Sequential Brands or the Company) (NASDAQ:SQBG).
  • If you suffered losses exceeding $50,000 investing in Sequential Brands stock or options and would like to discuss your legal rights, click here: www.faruqilaw.com/SQBG or call Faruqi & Faruqi partner James Wilson directly at 877-247-4292 or 212-983-9330 (Ext.
  • On December 11, 2020, the SEC filed a complaint against Sequential Brands alleging the Company failed to timely impair its goodwill as required by generally accepted accounting principles.
  • On this news, Sequential Brands stock fell sharply on December 11, 2020.

SEQUENTIAL BRANDS ALERT: Bragar Eagel & Squire, P.C. is Investigating Sequential Brands Group, Inc. on Behalf of Sequential Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, December 18, 2020

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Sequential Brands Group, Inc. (NASDAQ: SQBG) on behalf of Sequential stockholders.

Key Points: 
  • Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Sequential Brands Group, Inc. (NASDAQ: SQBG) on behalf of Sequential stockholders.
  • Our investigation concerns whether Sequential has violated the federal securities laws and/or engaged in other unlawful business practices.
  • On December 11, 2020, the SEC issued a press release titled SEC Charges Sequential Brands Group Inc. with Deceiving Investors by Failing to Timely Impair Goodwill.
  • Based on this news, shares of Sequential dropped sharply on the same day, to close at $16.20 per share.